Physician profile
Fahed A Saada
NPI 1316223613
$3,268.43
in general payments reported to CMS, 2019-2025
32 companies · $865 in 2025
The $865 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $90.63 · 2021: $361 · 2022: $328 · 2023: $670 · 2024: $755 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.83 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $341.63 | 2019-2025 | |
| Genentech USA, INC. | $295.99 | 2021-2025 | Ocrevus, Ocrevus Zunovo |
| Amgen INC. | $254.89 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $159.50 | 2022-2023 | Nuplazid |
| Lundbeck LLC | $146.28 | 2023-2025 | Vyepti |
| Astrazeneca Pharmaceuticals LP | $135.25 | 2023 | Andexxa, Farxiga |
| Eisai INC. | $125.00 | 2025 | |
| Lilly USA, LLC | $120.37 | 2023-2025 | Kisunla, Emgality, Amyvid |
| Medtronic, INC. | $115.79 | 2025 | Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $114.15 | 2022-2025 | Ultomiris, Soliris |
| Ucb, INC. | $105.25 | 2021-2025 | Fintepla, Nayzilam |
| Neurocrine Biosciences, INC. | $91.26 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $90.63 | 2020 | |
| Abbott Laboratories | $65.85 | 2019-2025 | Infinity |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $62.16 | 2019-2024 | Xarelto |
| Kyowa Kirin, INC. | $58.32 | 2023-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $53.50 | 2023-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $39.91 | 2024 | Rexulti |
| Emd Serono, INC. | $39.16 | 2023 | Mavenclad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.63 | 2024 | Jardiance, Synjardy |
| Sk Life Science, INC. | $28.37 | 2023 | |
| Biogen, INC. | $28.11 | 2021 | |
| Alk-Abello, INC | $24.64 | 2023 | Grastek, Ragwitek, Odactra |
| Novo Nordisk INC | $21.61 | 2021 | |
| Genzyme Corporation | $20.79 | 2021 | |
| Glaxosmithkline, LLC. | $19.16 | 2023 | Shingrix |
| Janssen Biotech, INC. | $18.61 | 2025 | |
| Livanova USA, INC. | $16.69 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Merck Sharp & Dohme LLC | $15.63 | 2024 | Gardasil 9, Vaxelis, Capvaxive |
| Boston Scientific Corporation | $15.11 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.36 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fahed Saada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.